Merck shares rise after Barclays upgrades shares, downgrades competitor Pfizer

Barclays upgraded Merck to overweight from equal weight on better opportunities versus its competition, while downgrading Pfizer to equal weight from overweight given the less likely chance of a "transformative" acquisition.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>